公开(公告)号：EP1957462A2

公开(公告)日：2008-08-20

申请号：EP06813006.1

申请日：2006-11-13

申请人： Astra Zeneca AB ,  Astex Therapeutics Limited

发明人： ALBERT, Jeffrey ,  CHESSARI, Gianni ,  CONGREVE, Miles, Stuart ,  EDWARDS, Phil ,  MURRAY, Christopher ,  PATEL, Sahil ,  SYLVESTER, Mark

IPC分类号： C07D217/22 ,  A61K31/4365 ,  A61K31/472 ,  A61K31/517 ,  A61K31/536 ,  A61P25/28 ,  C07D239/94 ,  C07D265/20 ,  C07D401/10 ,  C07D513/04

CPC分类号： C07D217/22 ,  C07D239/94 ,  C07D265/20 ,  C07D401/04 ,  C07D495/04

摘要： This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.

公开(公告)号：EP1893186A2

公开(公告)日：2008-03-05

申请号：EP06772643.0

申请日：2006-06-06

申请人： FIBROGEN, INC.

发明人： KLAUS, Stephen, J. ,  NEFF, Thomas, B.

IPC分类号： A61K31/00 ,  A61K31/44 ,  A61K31/47 ,  A61K31/496 ,  A61K31/17 ,  A61K31/4725 ,  A61K31/473 ,  A61K31/4365 ,  A61K33/26 ,  A61K38/18 ,  A61K45/06 ,  A61P7/06

CPC分类号： A61K45/06 ,  A61K31/00 ,  A61K31/17 ,  A61K31/4365 ,  A61K31/44 ,  A61K31/47 ,  A61K31/4704 ,  A61K31/4725 ,  A61K31/473 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/502 ,  A61K33/26 ,  A61K38/1816 ,  A61K2300/00

摘要： The present invention relates to improved methods for treating anemia. Compounds which stabilise HIF-alpha useful for treating anemia, wherein the anemia treatment is associated with a lower risk of thrombosis or hypertension compared to that observed with rhEPO therapy, are provided.

公开(公告)号：EP1888593A2

公开(公告)日：2008-02-20

申请号：EP06724792.4

申请日：2006-05-11

申请人： Merck Patent GmbH

发明人： EGGENWEILER, Hans-Michael ,  WOLF, Michael

IPC分类号： C07D495/04 ,  A61K31/4365 ,  A61P35/00

CPC分类号： C07D495/04

摘要： The invention relates to novel thienopyridine derivatives of formula (I), wherein R1, R2, R3, R4 and Y have the meaning cited in claim 1, are HSP90-inhibitors and can be used for producing a medicament for treating illnesses, wherein the inhibition, regulation and/or modulation of HSP90 plays a roll.

公开(公告)号：EP1888037A2

公开(公告)日：2008-02-20

申请号：EP06849772.6

申请日：2006-05-09

申请人： Elan Pharma International Limited

发明人： LIVERSIDGE, Gary, G. ,  JENKINS, Scott

IPC分类号： A61K9/14 ,  A61K31/4365

CPC分类号： A61K9/145 ,  A61K9/146 ,  A61K9/2018 ,  A61K31/4365

摘要： The present invention is directed to compositions comprising a nanoparticulate clopidogrel, or a salt or derivative thereof, having improved bioavailability. The nanoparticulate clopidogrel particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the prevention and treatment of pathologies induced by platelet aggregation. The clopidogrel particles may also be formulated as a controlled release polymeric coating or matrix drug delivery system.

公开(公告)号：EP1866318A2

公开(公告)日：2007-12-19

申请号：EP06737303.5

申请日：2006-03-02

申请人： FIBROGEN, INC.

发明人： TURTLE, Eric D. ,  FLIPPIN, Lee A. ,  AREND, Michael P. ,  CHENG, Heng

IPC分类号： C07D495/04 ,  A61P7/06 ,  A61K31/4365

CPC分类号： C07D495/04 ,  C07D498/02

摘要： The present invention relates to novel compounds of formula (I) capable of modulating the stability and/or activity of hypoxia inducible factor (HIF).

摘要翻译： 本发明涉及能够调节缺氧诱导因子（HIF）的稳定性和/或活性的新颖的式（I）化合物。

公开(公告)号：EP1851231A2

公开(公告)日：2007-11-07

申请号：EP06721049.2

申请日：2006-02-24

申请人： Teva Pharmaceutical Industries Ltd

发明人： TURGEMAN, Eran ,  MALACHI, Omer

IPC分类号： C07D495/04 ,  A61K31/4365 ,  A61P7/02

CPC分类号： C07D495/04

摘要： Provided is clopidogrel base suitable for pharmaceutical formulation, and processes for its preparation.

公开(公告)号：EP1848723A1

公开(公告)日：2007-10-31

申请号：EP06735273.2

申请日：2006-02-15

申请人： Achillion Pharmaceuticals, Inc.

发明人： BRADBURY, Barton, James ,  PAIS, Godwin ,  WANG, Qiuping ,  DESHPANDE, Milind ,  PUCCI, Michael, John ,  SONG, Yongsheng ,  LUCIEN, Edlaine ,  WILES, Jason ,  HASHIMOTO, Akihiro

IPC分类号： C07D513/04 ,  A61K31/437 ,  A61K31/4365 ,  A61P31/00 ,  C07D513/14

CPC分类号： C07D513/04 ,  C07D513/14

摘要： The invention provides certain compounds and salts of Formula I and Formula II:which possess antimicrobial activity. The invention also provides novel synthetic intermediatesuseful in making compounds of Formula I and Formula II. The variables A1, R2, R3, R5, R6, R7, A8, and Rg are defined herein. Certain compounds of Formula I and Formula II disclosed herein are potent and selective inhibitors of bacterial DNA synthesis and bacterial replication. The invention also provides antimicrobial compositions, including pharmaceutical compositions, containing one or more compounds of Formula I or Formula II and one or more carriers, excipients, or diluents. Such compositions may contain a compound of Formula I or Formula II as the only active agent or may contain a combination of a compound of Formula I or Formula II and one or more other active agents. The invention also provides methods for treating microbial infections in animals.

公开(公告)号：EP1562956A4

公开(公告)日：2007-10-10

申请号：EP03789996

申请日：2003-11-21

申请人： JAPAN TOBACCO INC

发明人： FOX BRIAN M ,  FURUKAWA N ,  HAO XIAOLIN ,  IIO K ,  INABA T ,  JACKSON SIMON M ,  KAYSER FRANK ,  LABELLE MARC ,  LI KEXUE ,  MATSUI T ,  MCMINN DUSTIN L ,  OGAWA N ,  RUBENSTEIN STEVEN M ,  SAGAWA S ,  SUGIMOTO K ,  SUZUKI M ,  TANAKA M ,  YE GUOSEN ,  YOSHIDA A ,  ZHANG JIAN

IPC分类号： A61K31/519 ,  A61K31/538 ,  A61K31/542 ,  C07D491/02 ,  C07D491/04 ,  C07D498/02 ,  C07D498/04 ,  C07D498/10 ,  C07D498/16 ,  C07D491/052 ,  A61K31/436 ,  A61K31/4365 ,  C07D513/04

CPC分类号： C07D491/04

公开(公告)号：EP1833836A1

公开(公告)日：2007-09-19

申请号：EP05849206.7

申请日：2005-11-10

申请人： Bristol-Myers Squibb Company

发明人： DYCKMAN, Alaric ,  BELEMA, Makonen ,  GILL, Patrice ,  KEMPSON, James ,  PITTS, William J. ,  QIU, Yuping ,  QUESNELLE, Claude ,  SPERGEL, Steven H. ,  ZUSI, F. Christopher

IPC分类号： C07D513/14 ,  A61K31/4365 ,  A61P35/00 ,  A61P29/02 ,  A61P37/02

CPC分类号： C07D513/14

摘要： The present invention provides for pyrazolopurine-based tricyclic compounds having the formula (I), wherein R1, R2, R3, and R6 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.

公开(公告)号：EP1820504A1

公开(公告)日：2007-08-22

申请号：EP05800461.5

申请日：2005-10-31

申请人： TAISHO PHARMACEUTICAL CO., LTD

发明人： SAITO, Shiuji, c/o TAISHO PHARMACEUTICAL CO. LTD. ,  OHTA, Hiroshi, c/o TAISHO PHARMACEUTICAL CO. LTD. ,  ISHIZAKA, Tomoko, TAISHO PHARMACEUTICAL CO. LTD. ,  YOSHINAGA, Mitsukane, TAISHO PHARMAC. CO. LTD. ,  TATSUZUKI, Makoto, TAISHO PHARMACEUTICAL CO., LTD. ,  YOKOBORI, Yuji, c/o TAISHO PHARMACEUTICAL CO. LTD. ,  TOMISHIMA, Yasumitsu, TAISHO PHARMAC. CO. LTD. ,  MORITA, Aki, c/o TAISHO PHARMACEUTICAL CO., LTD. ,  TODA, Yoshihisa, c/o TAISHO PHARMACEUTICAL CO. LTD ,  TOKUGAWA, Kimiko, TAISHO PHARMACEUTICAL CO. LTD. ,  KAKU, Ayaka, c/o TAISHO PHARMACEUTICAL CO., LTD. ,  MURAKAMI, Tomomi, TAISHO PHARMACEUTICAL CO. LTD. ,  YOSHIMURA, Hiromitsu, TAISHO PHARMAC. CO. LTD. ,  SEKINE, Shingo, c/o TAISHO PHARMACEUTICAL CO. LTD. ,  YOSHIMIZU, Takao, TAISHO PHARMACEUTICAL CO. LTD.

IPC分类号： A61K31/426 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/42 ,  A61K31/421 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/425 ,  A61K31/427 ,  A61K31/428 ,  A61K31/429 ,  A61K31/433 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/4409 ,  A61K31/4418 ,  A61K31/4427 ,  A61K31/443

CPC分类号： C07D417/12 ,  C07D213/75 ,  C07D231/40 ,  C07D401/12 ,  C07D409/12 ,  C07D413/12

摘要： An imine compound represented by the formula:

wherein A represents a heterocyclic group; R 1 , R 2 , an R 3 each represent a hydrogen atom, a halogen atom, a C 1-10 alkyl group optionally substituted with an aryl group(s) substituted with a halogen atom (s), a C 3-10 cycloalkyl group, a C 1-6 haloalkyl group, a C 1-10 alkoxy group, etc.; R 4 represents an optionally substituted C 1-10 alkyl, C 2-6 alkenyl, or aryl group; R 5 represents a hydrogen atom, a C 1-10 alkoxy group, a C 1-6 haloalkyl group, an optionally substituted C 1-10 alkyl or C 2-6 alkenyl group, an optionally substituted aryl or heterocyclic group, etc.; W represents -CO-, -CO-CO-, -CO-NH-, -CS-NH-, or -SO 2 -,
or a cannabinoid-receptor agonist comprising said imine compound as an active ingredient.
The imine compound of the present invention has a cannabinoid-receptor agonist effect, and is useful as a therapeutic or prophylactic drug for pains and autoimmune diseases.

摘要翻译： 由下式表示的亚胺化合物：其中A表示杂环基; R 1，R 2，R 3各自表示氢原子，卤素原子，任选被被卤素原子取代的芳基取代的C 1-10烷基，C 3-10环烷基 基团，C 1-6卤代烷基，C 1-10烷氧基等; R 4表示任选取代的C 1-10烷基，C 2-6烯基或芳基; R 5表示氢原子，C 1-10烷氧基，C 1-6卤代烷基，任选取代的C 1-10烷基或C 2-6烯基，任选取代的芳基或杂环基等; W表示-CO-，-CO-CO-，-CO-NH-，-CS-NH-或-SO 2 - 或包含所述亚胺化合物作为活性成分的大麻素受体激动剂。 本发明的亚胺化合物具有大麻素受体激动剂作用，可用作疼痛和自身免疫疾病的治疗或预防药物。